SMTL ID : 7pcd.1

HER2 IN COMPLEX WITH A COVALENT INHIBITOR

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.77 Å

Oligo State

monomer

Ligands

1 x 70I: 1-[4-[4-[[3,5-bis(chloranyl)-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]amino]pyrimido[5,4-d]pyrimidin-6-yl]piperazin-1-yl]-4-(3-fluoranylazetidin-1-yl)butan-1-one(Covalent)

70I.1: 20 residues within 4Å: Chain A: L.24, V.32, A.49, K.51, A.69, M.72, S.81, R.82, L.83, L.94, T.96, Q.97, M.99, C.103, D.106, R.147, L.150, T.160, D.161, F.162 6 PLIP interactions: 6 interactions with chain A Hydrophobic interactions: A:L.94, A:T.96 Hydrogen bonds: A:M.99 Salt bridges: A:D.106 pi-Stacking: A:F.162 Halogen bonds: A:L.94

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Wilding, B. et al., Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling. Nat Cancer (2022)

Release Date

2022-07-27

Peptides

Receptor tyrosine-protein kinase erbB-2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Receptor tyrosine-protein kinase erbB-2